Diagnostic and Prognostic Value of Hypoxia PET in Glioma: A Systematic Review and Meta-Analysis
Cancers · 10.06.2026 · 18 (12) · 1898
DOI: 10.3390/cancers18121898 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.06.2026. Verfasst von Aly Muhammad Ladak und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network, Sinai Health System & Women's College Hospital, T…. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: While MRI is effective for glioma diagnosis, it has limitations in grading, treatment planning, and prognostication. Since hypoxia is associated with higher-grade gliomas and poorer outcomes, PET imaging with hypoxia-specific tracers has been shown to improve glioma assessment. This systematic review and meta-analysis aimed to evaluate the performance of hypoxia PET imaging in glioma diagnosis and prognostication.
Methods
Systematic searches were conducted across PubMed, Web of Science, and Scopus through 31 January 2025. Only studies assessing the diagnostic or prognostic value of PET with 18F-labelled nitroimidazole (18F-FMISO, 18F-FAZA, 18F-FRP170, or 18F-FETNIM) or 62Cu-labelled ATSM hypoxia tracers in patients with gliomas were included. Hierarchical models were used to evaluate pooled performance on differentiating glioblastoma from lower-grade gliomas.
Results
Thirty-eight articles (n = 1156 patients) were eligible for inclusion, and eleven articles (n = 296 patients) were suitable for meta-analytical calculations. The extent of hypoxia on PET imaging was generally correlated with isocitrate dehydrogenase (IDH) mutation status and histological angiogenesis. Hypoxia PET was effective at differentiating glioblastoma from lower-grade gliomas and at predicting overall and progression-free survival. In a pooled analysis, 18F-FMISO PET displayed high sensitivity (98%) and specificity (94%) for differentiating glioblastoma from lower-grade gliomas.
Conclusions
Hypoxia PET has the potential to predict tumour biology, and it may be a reliable modality in combination with MRI to provide complementary information for glioma diagnosis, grading, treatment planning, and prognostication. It may be particularly useful for ruling out glioblastoma in patients with otherwise equivocal imaging; however, this would need to be validated prospectively with standardized image acquisition and interpretation criteria.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network, Sinai Health System & Women's College Hospital, Toronto, ON M5G 2N2, Canada.
- Department of Medical Imaging, Health Sciences North, Northern Ontario School of Medicine University, Sudbury, ON P3E 5J1, Canada.
ORCID-Profile: Aly Muhammad Ladak, Seyed Ali Mirshahvalad, Adam Farag, Ur Metser
Zitieren
APA
Ladak, A. M., Mirshahvalad, S. A., Farag, A., Metser, U., Ortega, C., Murad, V., & Veit-Haibach, P. (2026). Diagnostic and Prognostic Value of Hypoxia PET in Glioma: A Systematic Review and Meta-Analysis. Cancers, 18(12), 1898. https://doi.org/10.3390/cancers18121898
Vancouver
Ladak AM, Mirshahvalad SA, Farag A, Metser U, Ortega C, Murad V, et al. Diagnostic and Prognostic Value of Hypoxia PET in Glioma: A Systematic Review and Meta-Analysis. Cancers. 2026;18(12):1898. doi:10.3390/cancers18121898
BibTeX
@article{Ladak2026,
author = {Ladak, Aly Muhammad and Mirshahvalad, Seyed Ali and Farag, Adam and Metser, Ur and Ortega, Claudia and Murad, Vanessa and Veit-Haibach, Patrick},
title = {Diagnostic and Prognostic Value of Hypoxia PET in Glioma: A Systematic Review and Meta-Analysis},
journal = {Cancers},
year = {2026},
volume = {18},
number = {12},
pages = {1898},
doi = {10.3390/cancers18121898}
}
EUVIMED